We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why AbbVie (ABBV) Fell More Than Broader Market
Read MoreHide Full Article
In the latest trading session, AbbVie (ABBV - Free Report) closed at $203.71, marking a -2.24% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.24%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq lost 0.26%.
Shares of the drugmaker have appreciated by 1.61% over the course of the past month, outperforming the Medical sector's loss of 0.68%, and lagging the S&P 500's gain of 6.42%.
The upcoming earnings release of AbbVie will be of great interest to investors. The company's earnings report is expected on April 29, 2026. In that report, analysts expect AbbVie to post earnings of $2.69 per share. This would mark year-over-year growth of 9.35%. Meanwhile, our latest consensus estimate is calling for revenue of $14.78 billion, up 10.81% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $14.35 per share and a revenue of $67.01 billion, signifying shifts of +43.5% and +9.57%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.38% lower. AbbVie is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 14.53. This expresses no noticeable deviation compared to the average Forward P/E of 14.53 of its industry.
One should further note that ABBV currently holds a PEG ratio of 0.74. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 2.36 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 173, this industry ranks in the bottom 30% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why AbbVie (ABBV) Fell More Than Broader Market
In the latest trading session, AbbVie (ABBV - Free Report) closed at $203.71, marking a -2.24% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.24%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq lost 0.26%.
Shares of the drugmaker have appreciated by 1.61% over the course of the past month, outperforming the Medical sector's loss of 0.68%, and lagging the S&P 500's gain of 6.42%.
The upcoming earnings release of AbbVie will be of great interest to investors. The company's earnings report is expected on April 29, 2026. In that report, analysts expect AbbVie to post earnings of $2.69 per share. This would mark year-over-year growth of 9.35%. Meanwhile, our latest consensus estimate is calling for revenue of $14.78 billion, up 10.81% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $14.35 per share and a revenue of $67.01 billion, signifying shifts of +43.5% and +9.57%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.38% lower. AbbVie is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 14.53. This expresses no noticeable deviation compared to the average Forward P/E of 14.53 of its industry.
One should further note that ABBV currently holds a PEG ratio of 0.74. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 2.36 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 173, this industry ranks in the bottom 30% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.